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Background: Data are conflicting regarding the role of endogenous sex hormones in colorectal carcinogenesis. In this large
population-based study, we pooled data from birth and cancer registries in four Nordic countries, to evaluate the risk of colorectal
adenocarcinoma in relation to women’s reproductive history.
Methods: We conducted a population-based case–control study among women registered in Nordic birth registries. The study
included colorectal adenocarcinoma cases diagnosed in Denmark, Finland, Norway, and Sweden during 1967–2013 and up to 10
matched controls per case, in total 22 185 cases and 220 246 controls. Odds ratios (ORs) with 95% confidence intervals (95% CIs)
were derived from conditional logistic regression models. We had limited information available on possible confounders.
Results: We found no evidence for associations between colorectal adenocarcinoma and parity, age at first and last birth, and
time since first and last birth. The risk estimates were also close to unity for specific cancer subsites (proximal and distal colon and
rectum). As well, when the analyses were stratified on menopausal status, parity, and mother’s year of birth, no indication of
associations was found.
Conclusions: In this large, Nordic population-based study, no evidence for associations was found between women’s
reproductive history and colorectal adenocarcinoma in parous women.
Colorectal cancer is the second most common cancer in women
worldwide (GLOBOCAN 2012), and B55% of the cases occur
in more developed regions. In the Nordic countries during
2010–2014, the cumulative risk of disease before age 75 was 4.1%
in males and 3.2% in females (NORDCAN) (Engholm et al, 2010).
Median age at diagnosis was 69 years in males and 71 years
in females. The female incidence rate was highest in Norway
(36.2 per 100 000 person-years) and lowest in Finland (20.6 per
100 000 person-years).
Most cases of colorectal cancer are sporadic, and develop over
many years through the adenoma–carcinoma sequence (Brenner
et al, 2014). A family history of colorectal cancer (Taylor et al,
2010), inflammatory bowel disease (Ullman and Itzkowitz, 2011;
Jess et al, 2012), smoking (Liang et al, 2009), high alcohol
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consumption (Fedirko et al, 2011), high consumption of red and
processed meat (Bouvard et al, 2015), obesity (Ma et al, 2013), and
diabetes (Larsson et al, 2005) are established risk factors, while
physical activity (Boyle et al, 2012), aspirin/nonsteroidal anti-
inflammatory drug (NSAID) use (Friis et al, 2015; Drew et al,
2016), and endoscopic screening, with removal of precancerous
lesions (Elmunzer et al, 2012), have a protective effect.
As men have higher lifetime risk of colorectal cancer than
women, it has been speculated that oestrogen might have a role in
decreasing risk, at least partly mediated by oestrogen receptor
(ER)-beta, the predominant ER subtype in the human colon
(Campbell-Thompson et al, 2001). As opposed to the subtype
ER-alpha’s growth-promoting properties, ER-beta exerts an anti-
proliferative effect on non-transformed colonocytes (Zhao et al,
2010). A protective effect of oestrogens may also be mediated
through lower serum levels of insulin-like growth factor-I
(Campagnoli et al, 2003; Renehan et al, 2004) and decreases in
secondary bile acid production (McMichael and Potter, 1980;
Bayerdorffer et al, 1995). Colorectal cancer subsites, which have
been reported to vary by sex (Iacopetta, 2002; Lee et al, 2015),
exhibit differences in pathogenesis, genetic and epigenetic altera-
tions, and molecular pathways (Lee et al, 2015).
Strong evidence that exogenous hormones have a role in
colorectal carcinogenesis derives from observational studies and
clinical trials, which demonstrate an inverse relation between
postmenopausal hormone therapy (HT) use and risk of colorectal
cancer (Grodstein et al, 1999; Chlebowski et al, 2004; Lin et al,
2012). A meta-analysis, summarising results from cohort as well as
case–control studies, also reported a 20% reduction in colorectal
cancer risk among ever-users of oral contraceptives (OCs)
compared with never-users (Bosetti et al, 2009).
At the same time, epidemiologic data have been conflicting
regarding the role of endogenous sex hormones in colorectal
carcinogenesis. A US study on the role of reproductive history and
risk of colorectal cancer found positive associations between age at
menopause and age at first childbirth and colorectal cancer risk in
postmenopausal women, whereas age at menarche and parity were
inversely associated with risk (Zervoudakis et al, 2011). However, a
recent Swedish study found that higher parity was associated with
increased risk of adenocarcinoma of the proximal colon (Lu et al,
2014). In contrast, a study from the European Prospective
Investigation into Cancer and Nutrition found no association
between reproductive history and colorectal cancer risk (Tsilidis
et al, 2010). A 2013 meta-analysis also found no association between
age at menarche and risk of colorectal cancer (Li et al, 2013).
In our large population-based study, pooling data from birth and
cancer registries in four Nordic countries, we aimed to evaluate the
overall risk of colorectal adenocarcinoma, as well as risk by cancer
subsites, in relation to women’s reproductive history (parity, age at
first and last birth, and time since first and last birth), being a
surrogate measure of her lifetime exposure to endogenous sex steroids
or other biomarkers related to reproductive events.
MATERIALS AND METHODS
Data sources. This study was based on data collected from
nationwide population-based registries in the four Nordic
countries. Nordic birth registries contain information on all births
in Denmark, Finland, Norway, and Sweden since 1973, 1987, 1967,
and 1973, respectively (Gissler et al, 1997). Reporting of cancer
cases is compulsory in the Nordic countries, and the cancer
registries of Denmark, Finland, Norway, and Sweden cover the
entire national populations since 1943, 1952, 1953, and 1958,
respectively (Engholm et al, 2010). All residents of the four Nordic
countries are assigned a unique country-specific personal
identification number, which is used in all registries and makes
accurate record linkage possible.
Study design. The data were analysed within a case–control
design, including all colorectal adenocarcinoma cases diagnosed in
Denmark (1973–2011; n¼ 4680), Finland (1987–2012; n¼ 923),
Norway (1967–2013; n¼ 9797), and Sweden (1974–2013;
n¼ 6785) among women registered with a prior pregnancy (lasting
longer than 22 weeks) in the birth registries. The rationale for
including only parous women was to create a study group as
homogenous as possible with respect to fertility. We included only
the first cancer (any cancer) for each case. Up to 10 controls per
case were sampled among women in the birth registries with a
prior pregnancy lasting longer than 22 weeks, and they had to be
alive and free of any cancer at the time of diagnosis of the
corresponding case. Controls were matched to cases on country
and birth year of the case. In total 22 185 cases and 220 246
controls were included in the study.
Colorectal adenocarcinoma cases were identified using ICD-O-3
morphology codes in Denmark, Finland and Norway, and WHO/
HS/CANC/24.1 codes in Sweden. The following cancer subsites
were considered: proximal colon (ICD-10/ICD-O-3 (Denmark,
Finland, and Norway), C18.0–C18.5; and ICD-7 (Sweden),
153.0–153.1 and 153.4); distal colon (ICD-10/ICD-O-3, C18.6–C18.7;
and ICD-7, 153.2–153.3); other colon (ICD-10/ICD-O-3,
C18.8–C18.9; and ICD-7, 153.8–153.9); and rectum (ICD-10/
ICD-O-3, C19.9 and C20.9; and ICD-7, 154.0).
Statistical analysis. Odds ratios (ORs) with 95% confidence
intervals (95% CIs) were derived from conditional logistic
regression models. We examined the following reproductive
variables: parity – number of births at the time of matching
(1, 2, 3, and X4); age at first birth (o20, 20–29, 30–39, and
X40 years); age at last birth (o20, 20–29, 30–39, and X40 years);
time since first birth (o10, 10–19, 20–29, and X30 years); and
time since last birth (o10, 10–19, 20–29, and X30 years).
Stratified analyses were performed for ages o50, 50–59, and X60
years, which served as proxies for pre-, peri-, and postmenopausal
status, respectively. We had limited information available on
potential confounders.
We tested for differences between the countries by fitting logistic
regression models with and without interaction terms between country
of birth and the reproductive variables. The data were analysed using
IBM SPSS Statistics 22 (IBM Corporation, Armonk, NY, USA) and
Stata/IC 14.0 (StataCorp LP, College Station, TX, USA).
Ethical and legal considerations. This study was approved by the
ethical committees in Norway and Sweden. In Denmark, the study
was approved by the Data Protection Agency. In Finland, we
obtained permission to use health registry data from the National
Institute for Health and Welfare after approval by the data
protection authority.
RESULTS
Characteristics of the study population are presented in Table 1.
There were only minor differences between cases and controls.
Table 2 shows colorectal adenocarcinoma by subsites and country.
In total, 65% of cases had colon cancer (32% in the proximal colon
and 29% in the distal colon) and 35% had rectal cancer. Mean age
at diagnosis was 57 years (57 years for colon cancer and 56 years
for rectal cancer).
Table 3 displays ORs with 95% CIs obtained from univariate
analyses for colorectal adenocarcinoma according to reproductive
factors. We found no evidence for associations between colorectal
adenocarcinoma and parity, age at first and last birth, and time
since first and last birth. For specific subsites (proximal and distal
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colon and rectum) the risk estimates also were close to unity.
When the analyses were stratified on menopausal status (overall
and for specific subsites), parity, and mother’s year of birth
(o1950 and X1950) (data not shown), no evidence for
associations was found.
When we tested for potential differences between countries, no
significantly improved fit emerged of models including interaction
terms (data not shown).
DISCUSSION
In this large population-based Nordic study, no evidence for
associations was observed between women’s reproductive history
and colorectal adenocarcinoma in parous women.
Studies to date regarding reproductive factors and colorectal
cancer have been inconclusive. Our results showing no evidence for
associations between reproductive history and colorectal adeno-
carcinoma, accord with some studies (Troisi et al, 1997; Tsilidis
et al, 2010; Li et al, 2013), but not with others (Zervoudakis et al,
2011; Lu et al, 2014). A recent Swedish study, partly overlapping
with the Swedish data in our study, found that higher parity was
associated with increased risk of adenocarcinoma of the proximal
colon, both when parous women were compared with non-parous
women, and when analyses were restricted to parous women
(Lu et al, 2014). An earlier Norwegian study, partly overlapping
with the Norwegian data in our study, found associations between
parity and subsites of the colorectum (Kravdal et al, 1993).
However, in that study women with two or more children had a
lower risk of cancer in the caecum or ascending colon, compared
with non-parous women. A US study reported positive associations
between age at first birth and colorectal cancer in postmenopausal
women, whereas parity was inversely associated with risk in
women with no history of HT use (Zervoudakis et al, 2011).
The women included in our study were relatively young as our
study population was restricted to those being recorded with a
prior birth in the national birth registries; 26% of cases were below
age 50, and median age at diagnosis was 57 years. As median age at
diagnosis of patients with genetic syndromes is relatively low, that
is, in the fifth decade (Stoffel et al, 2009), it is possible that women
with hereditary forms of colorectal cancers were overrepresented in
our study population, and that these may have a weaker association
with reproductive factors than sporadic forms of the disease.
However, when we stratified on mother’s year of birth, no
difference in the risk estimates was observed.
Among the strengths of our study were its large size, inclusion
of all colorectal adenocarcinoma cases (more than 22 000), with
information on subsite, among women with at least one registered
pregnancy in the four Nordic countries, and linkage of compre-
hensive databases with valid information and mandatory reporting
(Teppo et al, 1994; Gissler et al, 1997; Barlow et al, 2009; Larsen
et al, 2009; Gjerstorff, 2011). The study design using standardised
data from registries also eliminated bias from participant self-
selection and recall bias.
Table 1. Characteristics of the study population, Nordic
countries, 1967–2013
Cases Controls
Variable n % n %
Year of birth
o1940 4292 19 42 860 19
1940–1949 9277 42 92 566 42
1950–1959 6059 27 60 243 27
1960–1969 2097 9 20 478 9
X1970 460 2 4099 2
Age at diagnosis/matching (years)
o40 1549 7 14 000 6
40–49 4250 19 42 490 19
50–59 7621 34 76 125 35
60–69 6533 29 65 372 30
X70 2232 10 22 259 10
Parity
1 2764 12 26 121 12
2 8646 39 85 954 39
3 6273 28 63 259 29
X4 4502 20 44 912 20
Age at first birth (years)
o20 870 4 8701 4
20–29 7871 35 77 992 35
30–39 2823 13 26 395 12
X40 179 1 1792 1
Missing 10 442 47 105 366 48
Age at last birth (years)
o20 129 1 1332 1
20–29 7992 36 78 976 36
30–39 12 481 56 124 256 56
X40 1583 7 15 682 7
Time since first birth (years)
o10 951 4 8071 4
10–19 2315 10 22 084 10
20–29 3789 17 37 898 17
X30 4688 21 46 827 21
Missing 10 442 47 105 366 48
Time since last birth (years)
o10 2447 11 22 158 10
10–19 4683 21 47 722 22
20–29 7275 33 73 216 33
X30 7780 35 77 150 35
Total 22 185 100 220 246 100
Table 2. Colorectal adenocarcinoma by subsite and country, Nordic countries, 1967–2013
Denmark (1973–2011) Finland (1987–2012) Norway (1967–2013) Sweden (1974–2013) Total (1967–2013)
Subsite n % n % n % n % n %
Colon
Proximala 1260 27 275 30 3492 36 2129 31 7156 32
Distalb 1458 31 268 29 2648 27 1949 29 6323 29
Otherc 205 4 43 5 457 5 300 4 1005 5
Rectumd 1757 38 337 37 3200 33 2407 35 7701 35
Total 4680 100 923 100 9797 100 6785 100 22 185 100
aProximal colon (ICD-10/ICD-O-3 (Denmark, Finland and Norway): C18.0–C18.5 and ICD-7 (Sweden): 153.0–153.1 and 153.4).
bDistal colon (ICD-10/ICD-O-3: C18.6–C18.7 and ICD-7: 153.2–153.3).
cOther colon (ICD-10/ICD-O-3: C18.8–C18.9 and ICD-7: 153.8–153.9).
dRectum (ICD-10/ICD-O-3: C19.9 and C20.9 and ICD-7: 154.0).
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A study weakness was lack of information on possible
confounders, such as use of exogenous hormones (OCs and HT),
age at menarche and menopause, obesity, smoking, physical
activity, and aspirin/NSAID use. It is possible that these factors act
in opposite directions, and thus contribute to an overall null effect.
However, in the Swedish study on reproductive history and
colorectal adenocarcinoma, adjustment for diabetes, obesity,
diagnoses associated with tobacco smoking and alcohol over-
consumption, as well as bilateral oophorectomy (representing HT)
did not change risk estimates materially (Lu et al, 2014).
A case–control design was chosen due to the strict confidenti-
ality and data protection legislation in the Nordic countries
covering access to data on the entire population and data exchange
between countries. Use of 10 controls per case approximated the
efficiency provided by a cohort design.
No data were missing for parity, age at last birth, and time since
last birth, whereas about 48% of women lacked data on age at first
birth and time since first birth, mostly due to the relatively recent
establishment of the birth registries. In Finland, where the birth
registry was established in 1987, more than 63% of women had
missing data on age at first birth. The relatively young age of the
Finnish cohort also strongly limits the number of cancer cases.
In conclusion, we found no evidence for associations between
women’s reproductive history (parity, age at first and last birth,
and time since first and last birth) and colorectal adenocarcinoma
in parous women.
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